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Background : Patients with diabetic nephropathy (DN) and coronary artery disease (CAD) represent a subset of 
patients with high cardiovascular morbidity and mortality. The optimal revascularization strategy using either 
percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) remains controversial. The purpose 
of this study was to compare the clinical outcomes of PCI to CABG in DN patients with CAD.
Methods : The clinical and angiographic records of DN patients with CAD who underwent either CABG (n=52) or 
PCI (n=48) were retrospectively analyzed.
Results :  The baseline characteristics were similar in the two groups except for the severity of the CAD. At 30 days, 
the death rate (PCI: 2.1% vs. CABG: 9.6%, p=0.21) and major adverse cardiac events (MACE) rate (PCI: 2.1 % vs. 
CABG: 9.6%, p=0.21) were similar in comparisons between the PCI and CABG groups. At three years, the death rate 
(PCI: 18.8% vs. CABG: 19.2%, p=0.94) was similar between the PCI and CABG groups but the MACE rate (PCI: 47.9% 
vs. CABG: 21.2%, p=0.006) was higher in the PCI group compared to the CABG group. In addition, the repeat 
revascularization rate was higher in the PCI group compared to the CABG group (PCI: 12.5% vs. CABG: 1.9%, p=0.046).
Conclusions :  The CABG procedure was associated with a lower incidence of MACE and repeat revascularization 
for up to three years of follow-up in DN patients with CAD. However, the overall survival rate was similar in the CABG 
and PCI groups. Therefore, CABG may be superior to PCI with regard to MACE and repeat revascularization.
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INTRODUCTION
Coronary artery disease (CAD) is highly prevalent in patients 
with diabetic nephropathy (DN) and the incidence of DN is 
increasing worldwide. Compared to nondiabetic patients, the 
postoperative morbidity and mortality are higher in diabetic 
patients after coronary artery bypass grafting (CABG) or 
percutaneous coronary intervention (PCI)1-3). Furthermore, the 
DN patients with CAD are a special subset of diabetic patients, 
who are known to be at a higher risk compared to diabetic 
patients without nephropathy4). The selection of the most 
appropriate revascularization strategy is important for improved 
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patient survival in DN patients with CAD. Angioplasty for 
multivessel CAD has become increasingly common for high-risk 
patients with comorbidities. However, a major drawback of 
percutaneous transluminal coronary angioplasty is the abrupt 
vessel closure and higher restenosis rates compared to the 
CABG procedure. Technical advances such as the use of a 
coronary stent have decreased the restenosis rates. However, 
CABG offers the advantage of a more complete revasculariza-
tion regardless of the coronary anatomy at the time of the 
procedure. Randomized trials of surgical therapy have shown 
that the benefits of surgical revascularization are proportional to 
the amount of myocardium affected by, or at risk for, ischemic 
injury5). Although, perioperative morbidity and mortality, duration 
of hospital stay and hospital cost is higher for CABG, several 
randomized clinical trials including the BARI (Bypass Angioplasty 
Revascularization Investigation) have suggested that CABG 
provided superior outcomes in the subgroup of diabetic patients 
due to better long-term patency of the grafts compared to PCI6,7). 
Therefore, contemporary PCI guidelines emphasize the 
long-term survival benefit with CABG for treatment of diabetics 
with multivessel CAD8). By contrast, survival data of 8818 
patients derived from seven registries showed a long-term 
mortality (5-12 years) of 27.8% in patients treated by PCI and 
26.3% in patients treated by CABG, revealing a mortality rate 
similar for the two groups9). The reason for the discrepancy 
between the subgroup analysis of the clinical and observational 
data is unclear, even though it is well known that CABG patient 
registries are usually much more clinically compromised than 
those for patients undergoing PCI. Although CABG appeared to 
provide a better outcome than PCI, most of the findings were 
obtained by subanalyses, without a focus on DN patients. 
The purpose of this study was to compare the clinical 
outcomes of a subset of diabetic patients with high cardiovas-
cular risk, DN patients with CAD, following PCI or CABG. 
MATERIALS AND METHODS
Patients
All clinical records and catheterization reports of type 2 
diabetic patients with nephropathy who underwent PCI or CABG 
at our institution from January 1, 1996 to December 31, 2005 
were retrospectively analyzed regarding clinical and angio-
graphic data. Diabetic nephropathy was defined as overt 
proteinuria (proteinuria > 500 mg/day) or a glomerular filtration 
rate (GFR) by the modified MDRD (Modification of Diet in Renal 
Disease) equation10) of less than 60 mL/min/1.73 m2. The 
revascularization strategy was determined by the clinical judg-
ment of the cardiologists and cardiac surgeons. In Brief, PCI 
was recommended for patients with single- or two-vessel 
disease with normal or slightly depressed global left ventricular 
function and for those with lesions anatomically suitable for the 
procedure. Whereas, surgery was preferred for patients with left 
main CAD or those who had two- or three-vessel disease with 
impaired global left ventricular function (left ventricular ejection 
fraction < 45%) or other lesions unsuitable for catheter- based 
procedures. Repeat revascularization was defined as 
angiographic ballooning or stenting due to angiographic 
restenosis at the site of previous stent deployment or graft, the 
development of new lesions or progression of untreated lesions 
on a coronary angiogram.
Pecutaneous coronary intervention procedures
Coronary angiography was performed by the femoral 
approach according to standard techniques. At least six 
standardized projections of the left coronary artery and two of 
the right coronary artery were obtained. The severity of the 
coronary artery disease was determined visually and was 
classified as single, double or triple vessel disease, defined by 
the presence of hemodynamically relevant stenosis (stenosis > 
50% of the luminal diameter) in one of the three major coronary 
vessels. A coronary lesion with critical stenosis (stenosis > 70% 
of the luminal diameter) was selected for coronary balloon 
angioplasty and stenting. Balloon angioplasty and commercially 
available bare metal stent implantation were performed 
according to standard techniques. The stent was deployed at 
the culprit lesion by inflating a balloon; inflation of the balloon 
expanded the stent. After the implantation of the stent, the 
stented area was often dilated further by standard balloon 
angioplasty techniques. The patients received 500 mg aspirin 
and 10,000 IU of heparin before the procedure. All patients were 
advised to take lifelong maintenance aspirin and another 
antiplatelet agent (clopidogrel, ticlopidine or cilostazol). 
Coronary artery bypass grafting
The bypass surgery followed current standard techniques, 
preferably with a left internal mammary artery for revascu-
larization of the left anterior descending coronary artery. Standard 
operative techniques for on-pump CABG for patients were used, 
including standard cardiopulmonary bypass, moderate hypothermia 
and cold potassium cardioplegia for myocardial protection. 
Off-pump CABG was performed using mechanical stabilization 
and intravascular shunting of the target coronary arteries.
Composite end points
The primary clinical end points were major adverse cardiac 
events (MACE) including death, myocardial infarction and repeat 
revascularization at 30 days, one year and three years. The 
secondary clinical end points were procedure related complica-
tions including stroke, post-procedural bleeding, pneumonia, 
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PCI
(n=48)
CABG
(n=52)
p-value
Age (years)
Male, n (%)
DM duration (years)
Hypertension, n (%)
Hypercholesterolemia, n (%)
Current smoking, n (%)
RAS blockade
CKD by eGFR 
  Stage 2, n (%)
  Stage 3, n (%)
  Stage 4, n (%)
  Stage 5, n (%)
Previous stroke, n (%)
Clinical presentation
  Stable angina, n (%)
  Unstable angina, n (%)
  Myocardial infarction, n (%)
Ejection fraction (%)
Previous myocardial infarction, n (%)
Vessel territory with stenosis 
  Left main coronary artery, n (%)
  Left anterior descending artery, n (%)
  Left circumflex artery, n (%)
  Right coronary artery, n (%)
No. of vessel territory with stenosis 
  One‐vessel disease, n (%)
  Two‐vessel disease, n (%)
    with p-LAD lesion
    without p-LAD lesion
  Three vessel disease, n (%)
No. of lesions with stenosis ≥ 50%
64.0±9.8
32 (66.7%)
13.8±9.3
39 (81.3%)
23 (52.3%)
10 (20.8%)
42 (87.5%)
2 (4.2%)
29 (60.4%)
9 (18.8%)
8 (16.7)
8 (16.7%)
18 (37.5%)
17 (35.4%)
9 (19.1%)
53.0±15.1
4 (8.3%)
0 (0.0%)
41 (85.4%)
34 (70.8%)
31 (64.6%)
7 (14.6%)
25 (52.1%)
6 (12.5%)
19 (39.6%)
16 (33.3%)
3.6±1.6
65.6±8.8
31 (59.6%)
13.5±9.9
45 (86.5%)
14 (32.6%)
2 (3.8%)
42 (80.8%)
3 (5.8%)
35 (67.3%)
5 (9.6%)
9 (17.3%)
3 (5.8%)
16 (30.8%)
26 (50%)
20 (38.5%)
52.7±15.8
9 (17.3%)
11 (21.2%)
50 (96.2%)
46 (88.5%)
49 (94.2%)
4 (7.7%)
4 (7.7%)
2 (3.8%)
2 (3.8%)
44 (84.6%)
5.1±2.0
0.16
0.47
0.88
0.47
0.06
0.009
0.42
0.61
0.08
0.48
0.14
0.035
0.91
0.18
0.001
0.08
0.028
<0.001
<0.001
<0.001
PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; DM, diabetes mellitus; RAS blockade, Use of 
renin-angiotensin system blocker; CKD, chronic kidney disease; eGFR, glomerular filtration rate estimated by modified MDRD 
(Modification of Diet in Renal Disease) study equation; p-LAD, proximal left anterior descending coronary artery
Table 1. Baseline clinical and angiographic characteristics 
renal failure requiring dialysis, and atrial flutter/atrial fibrillation at 
30 days. 
Statistical analysis
Continuous variables were expressed as mean±SD and 
were compared in the CABG and PCI groups by the Student's 
t-test. Categorical variables are presented as percentages and 
were compared by the chi-square test. For MACE, the event 
time was the number of days from the initial procedure to the 
first event. Time to death, time to MACE and time to repeat 
revascularization were evaluated at 30 days, one year and three 
years. Survival curves were generated using the Kaplan-Meier 
method. The Log-rank test was used to compare survival rates 
between CABG and PCI groups. In the subgroup analysis of 
CABG, according to type of surgery or graft, the Fisher's exact 
test was used to obtain the correlation of off-pump CABG or 
internal mammary artery with MACE or death. The multivariable 
Cox proportional hazards model was used to evaluate baseline 
clinical and angiographic characteristics and procedure-related 
variables in order to identify independent predictors of death 
and MACE. All statistical tests were two-tailed, and a 
significance level of 0.05 was used throughout. Statistical 
analyses were performed using SPSS version 12.0 (SPSS Inc., 
Chicago, Illinois, USA).
RESULTS
Baseline clinical characteristics and revascularization 
data
The pretreatment demographic and clinical characteristics 
and risk factors in the PCI and CABG groups were comparable, 
except for a significantly higher number of smokers in the PCI 
group and a greater number of patients presenting with 
myocardial infarction in the CABG group (Table 1). The CABG 
group had significantly more left main CAD (PCI group: 0% vs. 
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PCI
No. of stents implanted
Stent type
  Bare-metal stent, n (%)
Complete revascularization rate, n (%)
1.5±0.7
48 (100%)
12 (25.0%)†
CABG 
Off-pump CABG, n (%)
Grafts per patient
IMA graft to LAD, n (%)
Complete revascularization rate, n (%)
23 (44.2%)
2.5±1.4
46 (88.5%)
32 (61.5%)†
†Statistical significance between the PCI and CABG groups, 
p-value <0.001
PCI, percutaneous coronary intervention; CABG, coronary artery 
bypass grafting; IMA, internal mammary artery; LAD, left 
anterior descending coronary artery
Table 2. Procedural characteristics for PCI and CABG
CABG group: 21.2%, p= 0.001) and three vessel CAD (PCI: 
33.3% vs. CABG: 84.6%, p<0.001). The number of lesions with 
a greater than 50% stenosis was significantly higher in CABG 
group (PCI: 3.6±1.6 vs. CABG: 5.1±2.0, p<0.001) (Table 1). 
Off-pump CABG was performed in 44.2% of the patients in 
the CABG group; using a mean of 2.5±1.4 grafts per patient. 
An internal mammary artery graft to the left anterior descending 
artery was used in 88.5% of CABG patients (Table 2).
Commercially available bare metal stents were used in the 
PCI group. The number of lesions revascularized was 
significantly smaller in the PCI group than in the CABG group 
(PCI: 1.5±0.7 stents vs. CABG: 2.5±1.4 grafts, p<0.001). The 
complete revascularization rate was higher in the CABG group 
(PCI: 25.0% versus CABG: 61.5%, p<0.001) (Table 2).
30-day clinical outcomes 
In the CABG group, five patients died (9.6%) because of 
cardiogenic shock (n=2), hypovolemic shock due to postope-
rative bleeding (n=1), respiratory failure due to a possible stroke 
(n=1), and sepsis due to pneumonia (n=1). There was a 
spectrum of secondary adverse events in the CABG group: 
renal failure requiring dialysis (n=5), atrial fibrillation/atrial flutter 
(n=2), postoperative lung hemorrhage (n=1), and pneumonia 
(n=1). In the PCI group, one patient died due to cardiogenic 
shock. Secondary adverse events in the PCI group included 
renal failure requiring dialysis (n=1) and postoperative 
pneumonia (n=1). The MACE and death rates were comparable 
in the CABG and PCI groups (p=0.21) and the mean hospital 
stay was significantly shortened in the PCI group (PCI: 10.2±
6.7 vs. CABG: 18.7±7.7, p<0.001) (Table 3).
One-year clinical outcomes 
Between 31 days and one year, there were two deaths in the 
PCI group, one of which was cardiac related (sudden death 
possibly due to stent thrombosis). Between 31 days and one 
year, one patient in the PCI group had a myocardial infarction. 
This patient had an acute anterior wall myocardial infarction due 
to thrombotic occlusion of a first diagonal branch that had 
previously been stented. 
The MACE and death rates were comparable between the 
CABG and PCI groups while repeat revascularization rates were 
significantly higher in the PCI group (PCI: 12.5% vs. CABG: 
1.9%, p=0.046) (Table 3, Figure 1).
Three-year clinical outcomes 
Between one year and three years, there were six deaths in 
the PCI group and five deaths in the CABG group. The causes 
of death assigned to the PCI group were as follows: acute 
myocardial infarction (two patients), cerebral hemorrhage (one 
patient), aspiration pneumonia (one patient), renal failure (one 
patient), and cancer (one patient). In the CABG group, the 
causes of death were acute myocardial infarction (one patient), 
sepsis due to urinary tract infection (two patients) and sudden 
death (one patient). 
The MACE rate was lower in the CABG group than in the 
PCI group (PCI: 47.9% vs. CABG: 21.2%, p=0.006) and the 
death rate was comparable in the CABG and PCI groups 
(p=0.94). The repeat revascularization rate was significantly 
lower in the CABG group (PCI: 33.3% vs. CABG: 1.9%, 
p<0.001) (Table 3, Figure 2).
Subgroup analysis of the CABG group showed that the 
off-pump CABG and the on-pump CABG were not different in 
the death (off-pump CABG: 13% vs. on-pump CABG: 25%, 
p=0.48) and MACE rates (off-pump CABG: 17.4% vs. on-pump 
CABG: 25%, p=0.73). Internal mammary artery grafts provided 
greater protection from death (internal mammary artery grafts: 
13.3% vs. saphenous vein grafts: 66.7%, p=0.01, odds 
ratio=0.077) and MACE (internal mammary artery grafts: 15.6% 
vs. saphenous vein grafts: 66.7%, p=0.015, odds ratio=0.092) 
than the saphenous vein grafts.
Predictors of MACE and death 
The following variables were entered into a stepwise 
multivariable Cox proportional hazards model for MACE: age, 
gender, smoking history, GFR by the MDRD study equation, Ca 
X P product, uric acid, ejection fraction, myocardial infarction, 
prior stroke, peripheral vascular disease, therapy of lipid- 
lowering drug, and type of revascularization (CABG or PCI). The 
Cox proportional hazards regression model demonstrated that 
smoking history was a positive independent predictor (hazard 
ratio: HR, 1.030, 95% CI, 1.006 to 1.055) and CABG was a 
negative independent predictor (hazard ratio: HR, 0.189, 95% CI, 
0.064 to 0.556) of MACE (Table 4). 
The Cox proportional hazard regression model for death 
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PCI
 (n=48)
CABG 
(n=52)
p-value
30 days
  MACE, n (%)
  Death, n (%)
  Myocardial infarction, n (%)
  Repeat revascularization, n (%)
  Stroke, n (%)
  Postoperative bleeding, n (%)
  Postoperative pneumonia, n (%)
  Renal failure requiring dialysis, n (%)
  Atrial fibrillation/Atrial flutter, n (%)
  Length of in-hospital stay (days)
1 (2.1%)
1 (2.1%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
1 (2.1%)
1 (2.1%)
1 (2.1%)
10.2±6.7
5 (9.6%)
5 (9.6%)
0 (0%)
0 (0%)
0 (0%)
1 (1.9%)
1 (1.9%)
5 (9.6%)
2 (3.8%)
18.7±7.7
0.21
0.21
NA
NA
NA
0.33
0.95
0.11
0.61
<0.001
One year
  MACE, n (%)
  Death, n (%)
  Myocardial infarction, n (%)
  Repeat revacularization, n (%)
9 (18.8%)
3 (6.3%)
1 (2.1%)
6 (12.5%)
6 (11.5%)
5 (9.6%)
0 (0%)
1 (1.9%)
0.37
0.53
NA
0.046
Three years
  MACE, n (%)
  Death, n (%)
  Myocardial infarction, n (%)
  Repeat revacularization, n (%)
23 (47.9%)
9 (18.8%)
1 (2.1%)
16 (33.3%)
11 (21.2%)
10 (19.2%)
0 (0%)
1 (1.9%)
0.006
0.94
NA
<0.001
PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MACE, major adverse cardiac event; NA, not applicable
Table 3. 30-day, one-year and three-year clinical outcomes
Figure 1. Kaplan-Meier estimates of overall survival (A), MACE-free survival (B) and reintervention-free survival (C) at one year. Cum 
Survival, cumulative survival; MACE, major adverse cardiac event; CABG, coronary artery bypass grafting; PCI, percutaneous coronary 
intervention.
demonstrated that myocardial infarction was a positive 
independent predictor (hazard ratio: HR, 5.671, 95% CI, 1.230 to 
26.134) and higher GFR by the modified MDRD study equation 
was a negative independent predictor (hazard ratio: HR, 0.921, 
95% CI, 0.876 to 0.969) of death (Table 4).
DISCUSSION
This retrospective, observational study compared the clinical 
outcomes between PCI and CABG in DN patients with CAD. 
The overall survival was similar in the CABG and PCI groups 
but the MACE rates and incidence of repeat revascularization 
were significantly higher in the PCI group compared to the 
CABG group during follow up. PCI has been shown to be 
effective in reducing clinical symptoms in patients with CAD and 
myocardial ischemia. PCI may be the preferred strategy of 
myocardial revascularization in patients with serious systemic 
illness such as chronic renal failure and ESRD. The PCI 
procedures are less invasive than CABG and therefore are 
associated with less physical and psychological trauma. 
Compared to PCI, CABG is more invasive and the perioperative 
mortality and morbidity is very high especially in chronic renal 
failure patients. Furthermore, a longer hospital stay following 
A B C
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hazard ratio 95% confidence interval p-value
MACE
  CABG vs PCI
  Smoking history (PYs)
0.189
1.030
0.064-0.556
1.006-1.055
0.002
0.016
Death
  GFR by MDRD
  Presentation of MI
0.921
5.671
0.876-0.969
1.230-26.134
0.001
0.026
MACE, major adverse cardiac event; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; PYs, pack‐
years; GFR, estimated glomerular filtration rate; MDRD, modified Modification of Diet in Renal Disease study equation; MI, 
myocardial infarction
Table 4. Independent predictors for MACE and death
Figure 2. Kaplan-Meier estimates of total survival (A), MACE-free survival (B) and reintervention-free survival (C) at three years. Cum 
Survival, cumulative survival; MACE, major adverse cardiac event; CABG, coronary artery bypass grafting; PCI, percutaneous coronary 
intervention.
CABG results in higher hospital costs. It has been generally 
accepted that CABG is the preferred revascularization modality 
in DN patients with left main CAD or multivessel disease (three 
vessel or two vessel disease including proximal left anterior 
coronary artery lesion) with impaired left ventricular function 
(ejection fraction < 0.35) or complex lesions (total occlusion, 
calcified lesions, or bifurcation lesions)11). CABG has been 
associated with a higher incidence of significant adverse 
postoperative events. Therefore, in patients with serious illness 
such as chronic renal failure and ESRD, PCI can be an 
attractive alternative revascularization strategy to CABG. 
However, previously reported data do not provide support for 
either CABG or PCI as an initial strategy for diabetics with 
multivessel CAD who are at a high risk for adverse outcomes 
with CABG.
Our study on patients with DN showed that PCI resulted in 
outcomes comparable to CABG with respect to survival at three 
years. However, the repeat revascularization and MACE rates 
were significantly higher in the PCI group than in the CABG 
group at three years after the procedure. The anatomical 
patterns of CAD in the diabetic patients may influence their 
prognosis and response to revascularization. Previous studies 
have demonstrated that diabetic patients more frequently have 
left main coronary artery lesions, multivessel disease and diffuse 
CAD12,13). Our study results demonstrated that the CABG group 
had left main coronary artery lesions, multivessel disease, and 
diffuse CAD more frequently than the PCI group. However, the 
significantly higher complete revascularization rate in the CABG 
group (PCI: 25.0% vs. CABG: 61.5%, p<0.001) may have 
influenced the clinical outcomes. Until recently, no prospective 
trial has compared CABG with PCI in DN patients; post hoc 
analysis of trials has suggested favorable results with CABG in 
diabetics. The Arterial Revascularization Therapy Study (ARTS) 
compared the relative efficacy of CABG and multivessel bare 
metal stenting in diabetics and non-diabetics14). This study 
showed no difference in mortality between PCI and CABG in 
this subset of diabetics at one year. However, the revasculari-
zation rate clinically necessary in diabetics treated with PCI was 
twice as high as the revascularization rate in diabetics treated 
with CABG. The BARI reported that for patients who had 
diabetes, and symptomatic multivessel disease, CABG resulted 
in an improved five year survival rate (81%) compared to PTCA 
(65%). However, < 20% of patients had diabetes6). A large 
observational study of patients with multivessel disease reported 
that CABG was associated with higher adjusted long-term 
survival outcomes than PCI15). The CABG group included 
CA B
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patients with diabetes (33%), while 25% of the stented group 
were patients with diabetes. After the subgroup analysis of the 
patients with diabetes, hazard ratios for death were generally 
lower after CABG than after PCI. In the ARTS, 25% of patients 
had chronic kidney disease (CKD) at entry. CABG was 
associated with a reduced risk for revascularization compared 
with PCI10). In a recent meta-analysis, data were too sparse on 
renal disease patients to draw any definite conclusion16). 
However, the newly published Kidney Disease Outcomes 
Quality Initiative guidelines emphasized that outcomes in dialysis 
patients with established CAD are worse than outcomes in the 
general population. The guidelines support CABG as the 
preferred therapy for ESRD patients with three-vessel or left 
main CAD17). The complete revascularization rate with PCI in 
CKD patients ranges from only 25% to 50%18). Patients who 
have CKD and undergo PCI were more likely to have peripheral 
vascular disease, cerebrovascular disease, hypertension, and 
diabetes and may have clinically silent CAD19). The largest 
ESRD population studied was the US Renal Data System 
national database between 1978 and 1995. In nearly 7,000 
dialysis patients who underwent an initial PCI, the two-year 
survival rate was roughly 50%. Using the Cox regression model 
in this retrospective comparison, Herzog et al. showed that 
dialysis patients in the United States had better survival rates 
after CABG than after PCI20). Le Feuvre et al. reported a 
primary success rate of 96% in 21 dialysis patients, and the 
need for repeat intervention was similar to 187 control 
participants (30% vs. 25%). However, at two years, the rate of 
cardiac death was 15%, compared with 5% in the control 
group21). Furthermore, there was no significant difference in the 
mortality rate between PCI and CABG groups if they had the 
same left ventricular function22). Our study group was unique 
with regard to including patients with diabetes and nephropathy. 
Patients were included with CKD from stage 3 to stage 5 (95% 
of whole patients) and ESRD patients on dialysis (17% of whole 
patients). Diabetes mellitus and CKD are increasing in the 
general population and many of these patients require coronary 
revascularization procedures because of CAD. Renal 
insufficiency was reported as an independent predictor of the 
one-year mortality after PCI in a previous study19). Our study 
showed that decreased renal function was an independent 
predictor of the three-year mortality after PCI or CABG.
 Moreover, our study showed that the repeat revasculari-
zation rate was significantly higher in the PCI group compared 
to the CABG group. This observation may result from the fact 
that CABG is not associated with stent restenosis or stent 
thrombosis, and that arterial grafts may protect vessels from 
atherosclerotic progression and plaque rupture23, 24). In our 
study, about 89% of patients who had a CABG underwent an 
internal mammary artery graft. Progressive atherosclerosis was 
responsible for repeat revascularization in a significant number 
of diabetic patients25, 26). Progression of non-stented lesions was 
the reason for revascularization in 56% of patients who required 
repeat revascularization in our study. Furthermore, CABG 
provided a more complete revascularization rate than PCI 
(CABG: 61.5% vs. PCI: 25.0%, p<0.001). If one could effectively 
reduce restenosis in PCI, PCI would be a more attractive 
treatment modality than CABG. Recently published data 
demonstrated that the use of drug-eluting stents (DES) 
dramatically reduced the incidence of restenosis27). However, the 
outcomes of the studies using DES were not conclusive. 
Ben-Gal et al. reported that the midterm clinical outcome of 
diabetic patients treated surgically was better than that of 
patients undergoing PCI with DES despite improved results of 
PCI with DES28). Our study did not include patients who 
received a PCI with DES because DES was only recently 
introduced at our hospital. The number of patients who received 
PCI with DES is very small so it is impossible to obtain 
statistically meaningful results by comparing clinical outcomes of 
PCI with the bare metal stent group or the CABG group at 
three years. Our results showed that the treatment modalities 
(PCI or CABG) affected the MACE rate. CABG may be the 
preferred treatment modality for prevention of restenosis and for 
reducing the hospital cost for reintervention. However, PCI may 
be preferred for revascularization in severely ill patients.
Study limitations 
Our study has several important limitations. This study was a 
single-center, non-randomized, uncontrolled registry that 
requires validation by prospective randomized studies. 
Consequently, systematic comparison of long-term outcome 
was not available. The rate of MACE may be underestimated 
because of the absence of follow-up angiography and patient 
refusal of follow-up angiography and the possibility of silent 
ischemia. As only periprocedural, one-year and three-year 
outcomes were analyzed, a long-term follow-up study will be 
necessary to confirm our findings. Van Domburg et al. reported 
that a slight benefit, up to ten years, in favor of CABG among 
a diabetic subgroup was comparable to the results in the BARI 
trial. However, after ten years, both survival curves converged29). 
Another important limitation is that comparative studies of CABG 
and PCI can rapidly become outdated in view of evolving 
medical and technological procedural improvements. For 
example, triple therapy with antiplatelet agents (aspirin, 
clopidogrel and cilostazol), adjunctive use of glycoprotein IIb/IIIa 
inhibitor, new antirestenosis therapies such as DES, and 
coronary brachytherapy may reduce the need for reintervention 
and improve long-term outcome. In addition, surgical techniques 
for CABG continue to improve.
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Conclusions
CABG was associated with a lower incidence of MACE and 
repeat revascularization in the up to three-year follow-up of DN 
patients with CAD. However, the overall survival rate was similar 
in the CABG and PCI groups. CABG may be superior to PCI 
during this timeframe with respect to MACE and the repeat 
revascularization rate.
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